Axsome Therapeutics, based in New York City, develops therapies for central nervous system disorders, with commercial products Auvelity and Sunosi, and investigational drugs AXS-05 and AXS-07. The company employs 545 staff and went public in November 2015.
Mark Coleman sold 3,750 shares of AXSM on 27 May at $105.47 per share, worth a total of $396K. They now own 50,387 AXSM shares, or a 7% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
